Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538171 | 1.00 | OPRL1 (0.36) | OPRL1OPRM1OPRK1OPRD1BIRC2 | |
| SCHEMBL2312141 | 0.79 | SLC6A9 (0.52) | OPRL1OPRM1SLC6A9CACNA1ACACNA2D1 | |
| SCHEMBL2380937 | 0.78 | DRD2 (0.42) | OPRL1OPRM1ALDH1A1MAPK1 | |
| SCHEMBL2540365 | 0.77 | OPRM1 (0.35) | OPRL1OPRM1USP2ALDH1A1MAPK1 | |
| SCHEMBL2308976 | 0.77 | USP2 (0.57) | CACNA1ACACNA2D1CACNB1CACNA1CUSP2 | |
| SCHEMBL2380587 | 0.75 | PARP1 (0.40) | OPRL1OPRM1CNR2 | |
| SCHEMBL2310886 | 0.73 | USP2 (0.55) | CACNA1ACACNA2D1CACNB1CACNA1CUSP2 | |
| SCHEMBL2311801 | 0.73 | NPSR1 (0.44) | OPRL1OPRM1OPRK1OPRD1ALDH1A1 | |
| SCHEMBL2313152 | 0.72 | CACNA2D1 (0.59) | OPRL1OPRM1OPRK1OPRD1CACNA1A | |
| SCHEMBL2305958 | 0.72 | CACNA2D1 (0.59) | OPRL1OPRM1OPRK1OPRD1CACNA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | claimed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | claimed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | OPRL1 152/4885OPRM1 431/4885OPRK1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.